A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults

American Journal of Tropical Medicine and Hygiene

Volumn 88, Issue 1, 2013, Pages 73-88

  Thomas, Stephen J ^a   Eckels, Kenneth H ^a   Carletti, Isabelle ^b   De La Barrera, Rafael ^a   Dessy, Francis ^b   Fernandez, Stefan ^c   Putnak, Robert ^a   Toussaint, Jean Francois ^b   Sun, Wellington ^d   Bauer, Kristen ^c   Gibbons, Robert V ^e   Innis, Bruce L ^f  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b GSK   (Belgium)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e U S ARMY   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; EYE PAIN; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; VOMITING;

ADULT; DENGUE VACCINES; DENGUE VIRUS; HUMANS; PLACEBOS;

DENGUE VIRUS;

EID: 84872303811     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.12-0361     Document Type: Article

References (23)

1. WHO, 2012. Dengue and severe dengue, Fact sheet No 117. Available at: http://www.who.int/mediacentre/factsheets/fs117/en/index.html Jan 2012.
2. Thomas S, 2011. The necessity and quandaries of dengue vaccine development. J Infect Dis 203: 299-303.
3. Mustafa MS, Agrawal VK, 2008. Dengue vaccine: the current status. MJAFI 64: 161-164. (Pubitemid 351818953)
4. Pang T, Cardosa MJ, Guzman MG, 2007. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic feverdengue shock syndrome (DHF/DSS). Immunol Cell Biol 85: 43-45. (Pubitemid 46067320)
5. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DNC, Meltzer MI, 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22: 1275-1280. (Pubitemid 38296672)
6. Innis BL, Eckels KH, 2003. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 69: 1-4.
7. Edelman R, Wasserman S, Bodison S, Putnak R, Eckels K, Tang D, Kanesa-Thasan N, Vaughn D, Innis B, Sun W, 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (Suppl): 48-60.
8. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R, 2009. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirusnaive adults. Hum Vaccin 5: 33-40.
9. Simasathien S, Thomas SK, Watanaveeradej V, Nisalak A, Barberousse C, Innis B, Sunn W, Putnak R, Eckels K, Hutagalung Y, Gibbons R, Zhang C, De La Barrera R, Jarman R, Chawachalasai W, Mammen M, 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 78: 426-433. (Pubitemid 351845193)
10. Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, De La Barrera R, Mammen MP Jr, 2011. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 85: 341-351.
11. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH Jr, 2003. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 69 (Suppl): 12-16.
12. Lee IK, Lee WH, Liu JW, Yang KD, 2010. Acute myocarditis in dengue hemorrhagic fever: a case report and review of cardiac complications in dengue-affected patients. Int J Infect Dis 14: e919-e922.
13. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical Dictionary for Regulatory Activities and Maintenance and Support Services Organization. Version 14.0 01, March 2011. Available at: http://www.meddramsso.com. Accessed March 22, 2012.
14. Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A, Gibbons RV, Vassilev V, 2008. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J Virol Methods 153: 1-6.
15. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, Sun W, 2011. Immunological interference and facilitation between dengue serotypes in tetravalent formulations. J Infect Dis 204: 442-450.
16. De La C, Sierra B, Kourí G, Guzmán MG, 2007. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 152: 533-542. (Pubitemid 46363592)
17. Mackowiak PA, Wasserman SS, Tacket CO, Vaughn DW, Eckels KH, Dubois DR, Hoke CH, Edelman R, 1994. Quantitative relationship between oral temperature and severity of illness following inoculation with candidate attenuated dengue virus vaccines. Clin Infect Dis 19: 948 -950.
18. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS, 2000. Human skin Langerhans cells are targets of dengue virus infections. Nat Med 6: 816-820. (Pubitemid 30469433)
19. Durbin AP, Karron RA, Sun W, Vaughn D, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai C-J, Elkins WR, Chanock RM, Murphy BR, Whitehead SS, 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3¢-untranslated region. Am J Trop Med Hyg 65: 405-413. (Pubitemid 33134570)
20. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak AJ, 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. Infect Dis 181: 2-9. (Pubitemid 30049026)
21. Guy B, Saville M, Lang J, 2010. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 6: 696-705.
22. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP, 2009. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825-833.
23. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370-377.